Fernandes, Leonor, Vasconcelos de Matos, Leonor, Cardoso, Debora, Saraiva, Marlene, Medeiros-Mirra, Renata, Coelho, Andreia, Miranda, Helena and Martins, Ana 2020. Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review. CNS Oncology 9 (4) , CNS65. 10.2217/cns-2020-0023 |
PDF
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (967kB) |
|
Preview |
PDF
- Supplemental Material
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (136kB) | Preview |
Abstract
Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to its favorable toxicity profile and first-line indication in luminal ABC, appears promising in the setting of LMD, where symptom stabilization and quality-of-life preservation are the main goals; however, evidenced-based data are lacking. We conducted a thorough review of published evidence, aiming to investigate the role of ET in LMD treatment in luminal ABC. Twenty-one of 342 articles, evaluating 1302 patients, met inclusion criteria. ET use was rarely reported. New targeted agents show CNS activity. Research is lacking on the role of ET and targeted agents in BC-LMD treatment.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Dentistry |
Additional Information: | This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Publisher: | Future Medicine |
ISSN: | 2045-0907 |
Date of First Compliant Deposit: | 10 June 2022 |
Date of Acceptance: | 2 October 2020 |
Last Modified: | 05 Oct 2023 21:49 |
URI: | https://orca.cardiff.ac.uk/id/eprint/150418 |
Actions (repository staff only)
Edit Item |